Will moboxetinib enter medical insurance in 2024? Come and check it out

Mobocertinib, sold under the trade nameExkivity/Mobocertinib (Mobocertinib) is used to treat non-small cell lung cancer (NSCLC), The original drug of mobosetinib is currently on the market in China and has not yet been included in the medical insurance. The specific time of entering the medical insurance is not yet clear, but there is hope that it will be included in the medical insurance. Patients can consult at the local medical insurance bureau or hospital.

Mobosetinib is a small molecule tyrosine kinase inhibitor that is structurally similar to osimertinib. The only difference is that it has an additional isopropyl ester group. Its molecular target is epidermal growth factor receptor (EGFR) with mutations in the exon 20 region. Mobosetinib is an irreversible kinase inhibitor that forms a covalent bond with cysteine u200bu200b797 in the active site of EGFR, resulting in sustained inhibition of EGFR enzyme activity. Irreversible binding results in increased potency through higher affinity binding, longer-lasting inhibition of EGFR kinase activity, and greater overall selectivity because only a limited number of other kinases have cysteine u200bu200bat the same position.

Mobosetinib original drug sold in China, the common specification40mg*112 pills per box, is very expensive.The Hong Kong version of the original drug specification40mg*30 pills per box is priced at more than 7,000 RMB (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.